Home › Research › Treatments
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne, David James Brooks, Martin N. Rossor, Nick C. Fox, Roger Alan Bullock, William E. Klunk, Chester A. Mathis, Kaj Blennow, Jerome A. Barakos, Aren Okello, Sofia Rodriguez Martinez de Liano, Enchi Liu, Martin Koller, Keith M. Gregg, Dale Schenk, Ronald S. Black, Michael Grundman. The Lancet Neurology, 2010-02-27
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We do not hold a plain-English summary of this study yet. Use the links to the original below for its abstract and findings.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R. A., Klunk, W. E., et al. (2010). 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(10)70043-0
Vancouver
Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock RA, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. The Lancet Neurology. 2010. doi:10.1016/s1474-4422(10)70043-0. PMID: 20189881.
BibTeX
@article{rinne2010-20189881,
author = {Rinne, Juha O. and Brooks, David James and Rossor, Martin N. and Fox, Nick C. and Bullock, Roger Alan and Klunk, William E. and Mathis, Chester A. and Blennow, Kaj and Barakos, Jerome A. and Okello, Aren and de Liano, Sofia Rodriguez Martinez and Liu, Enchi and Koller, Martin and Gregg, Keith M. and Schenk, Dale and Black, Ronald S. and Grundman, Michael},
title = {{11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study}},
journal = {The Lancet Neurology},
year = {2010},
doi = {10.1016/s1474-4422(10)70043-0},
pmid = {20189881},
url = {https://doi.org/10.1016/s1474-4422(10)70043-0}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 17 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Why it matters
A phase 2, double-blind, placebo-controlled, ascending-dose study used 11C-PiB PET scans to assess change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab.
New to this subject? Start with our plain-English guide: Treatments →
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 52 of the 95 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 702 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 39.0 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 6 / 6 | Cited 57.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Michael Grundman: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20189881) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 52 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 52 of the 95 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.